1. Introduction

Social inequality risks from enhancement access refer to the legal, ethical, economic and social inequalities that arise when advanced biological, genetic, neurological, pharmaceutical or technological enhancements are available only to certain sections of society.

Human enhancement refers to the use of biotechnology and scientific interventions to improve human physical, intellectual, cognitive, reproductive or psychological capabilities beyond ordinary therapeutic treatment.

Examples include:

Genetic enhancement: Editing genes to improve physical characteristics, disease resistance or other inherited traits.

Cognitive enhancement: Using neurotechnology, brain stimulation or pharmaceutical interventions to improve memory, concentration and intelligence.

Physical enhancement: Using advanced prosthetics, implants and biological interventions to improve strength, endurance or physical performance.

Reproductive enhancement: Selecting embryos or modifying genetic characteristics to influence the characteristics of future children.

Longevity enhancement: Using biotechnology to extend healthy lifespan or slow biological ageing.

The central legal concern is that wealthy individuals may obtain access to these technologies while economically disadvantaged individuals remain excluded. This could create a society in which biological advantages become connected to financial wealth, educational opportunities, employment prospects and social status.

Consequently, enhancement access raises questions of equality before law, human dignity, informed consent, non-discrimination, distributive justice and the protection of future generations.

2. Meaning and Nature of Social Inequality in Enhancement Access

Social inequality in enhancement access occurs when individuals or groups have unequal opportunities to obtain technologies that improve human capabilities.

It can develop through several mechanisms:

Economic inequality: Expensive enhancement procedures may be accessible only to wealthy individuals.

Educational inequality: Enhanced cognitive abilities could create additional advantages in academic competition.

Employment inequality: Employers may indirectly favour enhanced workers over individuals who cannot afford enhancement.

Genetic inequality: Wealthy families may obtain reproductive or genetic technologies that give their children inherited advantages.

Healthcare inequality: Enhancement technologies may receive greater investment than basic healthcare services.

Geographical inequality: Advanced biotechnology may be concentrated in developed countries and major urban centres.

Intergenerational inequality: Advantages obtained by one generation may be transferred to future generations through inherited genetic modifications.

The legal challenge is to distinguish legitimate medical treatment from enhancement practices that may produce unfair social advantages.

3. Major Legal and Social Risks

A. Creation of a Genetic and Biological Elite

One of the most serious risks is the emergence of a genetic or biological elite.

If wealthy families can purchase genetic enhancement, embryo selection or advanced biological interventions, their children may obtain advantages in physical development, health or cognitive abilities.

Over several generations, these advantages could become associated with economic privilege.

This may result in:

Biological stratification between wealthy and poor communities.

Increased discrimination against non-enhanced individuals.

Concentration of scientific and economic power.

Social perceptions that certain genetic characteristics are superior.

A new form of inherited privilege.

The concern resembles historical eugenics, in which governments and institutions attempted to classify people according to allegedly desirable biological characteristics.

Legal implications: Equality before law, human dignity, reproductive autonomy and protection against discrimination must apply regardless of genetic characteristics.

B. Economic Discrimination and Unequal Opportunities

Enhancement technologies may become expensive commercial services.

For example, imagine two candidates applying for the same employment position. One has access to expensive cognitive enhancement, while the other has ordinary cognitive abilities but equal qualifications and professional experience.

If employers begin preferring enhanced candidates, economic inequality could become a basis for biological discrimination.

This could affect:

Recruitment and promotion.

Competitive examinations.

Military and security employment.

Professional licensing.

Sports competitions.

Access to educational institutions.

The law must determine whether enhancement is a voluntary personal choice or an indirect condition imposed by employers and institutions.

C. Educational Inequality

Cognitive enhancement could create unequal educational opportunities.

Students with access to memory-enhancing pharmaceuticals, neurotechnology or future genetic interventions may obtain advantages in examinations and academic competitions.

Children from economically disadvantaged families may be unable to obtain comparable technologies.

This could undermine the principle of equality of opportunity.

An important distinction must be maintained between providing medical assistance to children with disabilities and providing elective enhancement for competitive advantage.

D. Discrimination Against Non-Enhanced Individuals

A further risk is the emergence of discrimination based on enhanced and non-enhanced status.

Possible discriminatory practices include:

Refusing employment to non-enhanced individuals.

Charging different insurance premiums based on enhancement status.

Giving enhanced students preferential admission.

Treating genetically unmodified individuals as less capable.

Excluding non-enhanced athletes from professional competitions.

Such practices could create a new category of social exclusion.

E. Reproductive Inequality and Designer Children

Reproductive enhancement may allow wealthy parents to select certain genetic characteristics for their children.

If genetic modification becomes sufficiently advanced and is considered safe for particular applications, access may initially remain concentrated among wealthy families.

This raises questions about parental freedom, the future child's autonomy and the rights of future generations.

The concern is not simply that parents make reproductive decisions. It is that commercial and social pressures could encourage parents to select characteristics associated with wealth, intelligence, appearance or social acceptability.

This could reinforce existing prejudices and discriminatory attitudes towards disability and human diversity.

F. Healthcare Resource Allocation

Governments may face difficult decisions when allocating limited healthcare resources.

For example, should public funds be spent on expensive cognitive or physical enhancement procedures when large sections of the population lack basic medical facilities?

A fair healthcare system must distinguish between:

Essential medical treatment.

Preventive healthcare.

Disability-related interventions.

Elective enhancement.

Experimental enhancement.

The availability of enhancement technology does not automatically create an entitlement to receive every enhancement through public healthcare.

However, governments must ensure that enhancement policies do not undermine access to essential healthcare.

G. International Inequality

Enhancement technologies may initially be concentrated in technologically advanced countries.

This could create disparities between:

Developed and developing countries.

Urban and rural populations.

Public and private healthcare systems.

High-income and low-income communities.

International biotechnology companies may also control patents, research infrastructure and access to advanced genetic technologies.

Consequently, international cooperation is necessary to prevent scientific progress from increasing existing global inequalities.

4. Important Case Laws and Judicial Principles

There is currently no established body of judicial decisions directly deciding whether unequal access to elective human enhancement is unconstitutional. However, several important judgments concerning equality, genetic discrimination, reproductive autonomy, healthcare and human dignity provide relevant legal principles.

Case 1: United India Insurance Co. Ltd. v. Jai Parkash Tayal (2018)

Highly relevant Indian judgment

Court: Delhi High Court

Date: 26 February 2018

Citation: RFA 610/2016.

Facts:

The dispute concerned a health insurance policy containing an exclusion for genetic disorders.

Jai Parkash Tayal suffered from hypertrophic obstructive cardiomyopathy. The insurance company relied on the genetic-disorder exclusion to reject his claim.

Legal issue:

Whether insurance companies could broadly exclude individuals from coverage merely because they suffered from genetic disorders.

Judgment:

The Delhi High Court held that a broad and ambiguous exclusion of genetic disorders was discriminatory and violative of Article 14 of the Indian Constitution.

The Court emphasized that genetic discrimination in health insurance could undermine the right to healthcare and the right to health under Article 21.

It also highlighted the need for appropriate regulation of genetic testing and confidentiality of genetic information.

Indian Kanoon

Connection with enhancement inequality:

This judgment is important because it establishes a judicial basis for challenging arbitrary treatment of individuals based on genetic characteristics.

If insurers discriminate between enhanced and non-enhanced individuals without reasonable and legally defensible grounds, similar equality concerns may arise.

Important subsequent development: The insurance company approached the Supreme Court. On 27 August 2018, the Supreme Court issued notice and stayed the operation of the Delhi High Court's specified conclusions and relief pending further proceedings. Therefore, the Delhi High Court's conclusions should not be presented as an unqualified final Supreme Court ruling.

Indian Kanoon

Case 2: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Court: Supreme Court of India

Citation: (2017) 10 SCC 1.

Facts:

The case concerned whether the right to privacy was constitutionally protected under the Indian Constitution.

Judgment:

The nine-judge Constitution Bench unanimously recognised privacy as a fundamental right under Article 21 and as an important element of liberty, dignity and individual autonomy.

The judgment recognised informational privacy and the individual's interest in controlling personal information.

Connection with enhancement inequality:

Human enhancement may involve the collection of:

Genetic information.

Neurobiological information.

Reproductive information.

Cognitive performance data.

Personal biological characteristics.

If employers, insurers or educational institutions misuse such information to classify individuals, privacy and autonomy concerns arise.

The principles in Puttaswamy are therefore important for regulating enhancement-related biological data and preventing discriminatory profiling.

Sci API

Case 3: Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996)

Court: Supreme Court of India

Citation: (1996) 4 SCC 37.

Facts:

A seriously injured individual was denied appropriate medical assistance at several government hospitals because adequate facilities were unavailable.

Judgment:

The Supreme Court held that failure by government hospitals to provide timely medical treatment violated Article 21.

It recognised the constitutional obligation of the State to provide adequate medical facilities and directed improvements in the healthcare system.

Connection with enhancement inequality:

This case provides an important foundation for the principle that technological advancement should not distract governments from their constitutional responsibilities towards essential healthcare.

If governments allocate excessive public resources to elective enhancement while neglecting essential medical facilities, questions of healthcare priorities and constitutional obligations may arise.

Indian Kanoon+1

Case 4: Skinner v. Oklahoma ex rel. Williamson (1942)

Court: United States Supreme Court

Citation: 316 U.S. 535 (1942).

Facts:

Oklahoma enacted legislation permitting compulsory sterilisation of certain habitual offenders.

The law treated different categories of offenders differently.

Judgment:

The United States Supreme Court invalidated the legislation under the Equal Protection Clause of the Fourteenth Amendment.

The Court recognised the fundamental importance of procreation and stressed the danger of discriminatory state intervention in reproductive rights.

Connection with enhancement inequality:

Skinner is particularly relevant to the historical dangers of eugenic policies.

It demonstrates why governments must exercise exceptional care when biological characteristics, reproduction and social classifications intersect.

A state-sponsored system that rewards supposedly superior genetic characteristics while disadvantaging other groups could raise similar constitutional concerns.

Justia U.S. Supreme Court Center

Case 5: Suchita Srivastava v. Chandigarh Administration (2009)

Court: Supreme Court of India

Citation: (2009) 9 SCC 1.

Facts:

The case concerned the reproductive rights of a woman with an intellectual disability and whether the State could compel termination of her pregnancy.

Judgment:

The Supreme Court recognised reproductive choice as an important aspect of personal liberty under Article 21.

It emphasised the importance of reproductive autonomy and informed consent.

Connection with enhancement inequality:

This judgment is relevant to reproductive enhancement, embryo selection and genetic modification.

It supports the principle that reproductive decisions must respect individual autonomy and cannot be determined merely by institutional preferences about desirable biological characteristics.

It also raises concerns about coercive enhancement programmes and discriminatory reproductive policies.

Case 6: National Legal Services Authority v. Union of India (2014)

Court: Supreme Court of India

Citation: (2014) 5 SCC 438.

Facts:

The case concerned the constitutional recognition and rights of transgender persons.

Judgment:

The Supreme Court recognised transgender persons' rights to equality, dignity, identity and equal protection under Articles 14, 15, 16 and 21.

Connection with enhancement inequality:

The decision provides an important constitutional foundation for protecting people from discrimination based on biological characteristics and identity.

Enhancement technologies must not become instruments for defining certain physical or biological characteristics as socially superior.

The decision supports a human-rights approach in which human dignity does not depend on biological conformity or technological modification.

Case 7: Minister of Health v. Treatment Action Campaign (No. 2) (2002)

Court: Constitutional Court of South Africa

Citation: 2002 (5) SA 721 (CC).

Facts:

The case concerned restrictions on the availability of the antiretroviral medicine Nevirapine to prevent mother-to-child transmission of HIV.

Judgment:

The Constitutional Court found that the government's restrictions were unreasonable and inconsistent with its constitutional obligations concerning access to healthcare.

Connection with enhancement inequality:

The decision provides a comparative constitutional principle: public healthcare policy must take account of the needs of vulnerable populations and cannot impose unjustified restrictions on access to medically necessary interventions.

It is relevant when considering whether advanced biological technologies should be distributed in ways that ignore economically disadvantaged communities.

5. Indian Constitutional Framework

Social inequality arising from enhancement access can be examined through several constitutional provisions.

Article 14 is particularly significant. If a government or public institution creates classifications based on enhanced and non-enhanced biological characteristics, those classifications must satisfy constitutional requirements of non-arbitrariness and equality.

Article 38 also provides an important policy foundation for reducing inequalities in income, status, facilities and opportunities.

6. International Legal Framework

Several international instruments provide principles relevant to the regulation of human enhancement.

A. Universal Declaration of Human Rights, 1948

Article 1: All human beings are born free and equal in dignity and rights.

Article 2: Protection against discrimination.

Article 7: Equality before the law.

Article 25: Right to an adequate standard of living and medical care.

These provisions support the principle that access to scientific progress should not undermine human dignity or equal legal status.

B. International Covenant on Economic, Social and Cultural Rights, 1966

Article 12 recognises the right to the highest attainable standard of physical and mental health.

Article 15 recognises the right to enjoy the benefits of scientific progress and its applications.

Article 15 is especially relevant because it connects scientific advancement with the public's interest in accessing its benefits.

C. UNESCO Universal Declaration on the Human Genome and Human Rights, 1997

The Declaration recognises the human genome as a fundamental element of humanity's common heritage.

Its principles emphasise human dignity, equality, non-discrimination and protection against genetic discrimination.

D. UNESCO Universal Declaration on Bioethics and Human Rights, 2005

Important provisions include:

Article 3: Human dignity and human rights.

Article 8: Respect for human vulnerability and personal integrity.

Article 10: Equality, justice and equity.

Article 11: Non-discrimination and non-stigmatisation.

Article 15: Sharing of benefits.

Article 16: Protection of future generations.

Article 15 is particularly relevant because it promotes sharing the benefits of scientific research, especially with disadvantaged populations.

7. Major Regulatory Challenges

The following challenges require particular attention.

1. Defining enhancement and treatment

Regulators must distinguish between interventions intended to treat medical conditions and interventions intended to provide competitive advantages.

This distinction can be difficult because the same technology may have therapeutic and enhancement applications.

2. Establishing fair access

Governments must decide whether particular technologies should be publicly funded, subsidised or restricted to specific medical indications.

3. Preventing enhancement-based employment discrimination

Employers should not automatically assume that enhanced individuals are more competent than non-enhanced individuals.

Employment decisions should be based on legitimate job requirements and objective qualifications.

4. Protecting children

Children should not be subjected to unnecessary or experimental enhancement procedures merely to satisfy parental expectations or competitive social pressures.

5. Protecting persons with disabilities

Enhancement policies must not reinforce the assumption that people with disabilities have inferior human worth.

6. Preventing genetic monopolies

Excessive concentration of intellectual property rights and commercial control over essential biological technologies may restrict public access.

7. Regulating insurance practices

Insurance companies should not impose arbitrary exclusions or discriminatory conditions based solely on genetic or enhancement-related information.

8. Suggested Legal and Policy Safeguards

A comprehensive regulatory framework should incorporate the following measures:

9. Critical Legal Analysis

The central question is whether equality requires everyone to receive identical enhancement technologies or whether it requires a fair distribution of opportunities and benefits.

These are different approaches.

Formal equality requires equal treatment under the law.

Substantive equality recognises that people begin from different economic, social and biological circumstances and may require different levels of assistance to enjoy genuinely equal opportunities.

For example, providing a costly medical intervention to a person with a serious disability may promote substantive equality rather than create an unfair advantage.

Conversely, allowing wealthy individuals to purchase elective enhancements that create substantial competitive advantages could reinforce existing social divisions.

The Rawlsian theory of distributive justice offers a useful analytical framework. Under this approach, social and economic inequalities require justification, particularly in relation to their effects on the least advantaged members of society.

However, equal distribution of enhancement technologies alone may not eliminate inequality. Education, nutrition, family environment, healthcare infrastructure and economic opportunities also influence the benefits individuals obtain from biological enhancements.

Consequently, regulation must address both access to technology and the social conditions necessary to benefit from it.

10. Conclusion

Social inequality risks from enhancement access represent an important emerging issue in biotechnology law and human-rights governance.

Advanced genetic, cognitive, reproductive and physical enhancement technologies may provide substantial benefits. However, unequal access could create new forms of biological discrimination, economic stratification and inherited privilege.

Indian constitutional principles under Articles 14 and 21 provide important foundations for addressing these concerns. Decisions such as Puttaswamy, Jai Parkash Tayal, Paschim Banga Khet Mazdoor Samity and Suchita Srivastava provide relevant judicial principles concerning privacy, genetic discrimination, healthcare and reproductive autonomy.

International human-rights instruments similarly emphasise equality, dignity, non-discrimination and sharing the benefits of scientific progress.

Ultimately, the law should ensure that scientific advancement expands human opportunity rather than converting economic privilege into permanent biological privilege.

11. Important Authorities for Academic Research

Further academic reading:

Enhancements and Justice – Ronald A. Lindsay (2005).

The Impact of Genetic Enhancement on Equality – Michael H. Shapiro.

Genetic Enhancement, Social Justice, and Welfare-Oriented Patterns of Distribution.

National Academies – Human Genome Editing: Science, Ethics, and Governance.

Regulating Genome Editing Under International Human Rights Law.

These materials provide a foundation for research into the relationship between biotechnology, distributive justice, constitutional equality and human enhancement governance.